A combination vinorelbine-estramustine in patients with hormone refractory prostate cancer

被引：0
|
作者：
Butera, A. [1 ]
Tornabene, P. [1 ]
机构：
[1] UO Oncol Med AOS Giovanni Dio Agrigento, Vicenza, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82 / 82
页数：1
相关论文
共 50 条
  • [41] WEEKLY EPIRUBICIN PLUS ORAL ESTRAMUSTINE IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER
    Ramus, Guido Vietti
    Tonda, Laura
    Sirgiovanni, Marianna Paola
    ANNALS OF ONCOLOGY, 2004, 15 : 95 - 95
  • [42] Weekly paclitaxel plus estramustine phosphate in hormone-refractory prostate cancer
    Roth, BJ
    Hudes, GR
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 137 - 137
  • [43] PACLITAXEL PLUS ESTRAMUSTINE IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER
    HUDES, GR
    NATHAN, FE
    KHATER, C
    GREENBERG, R
    GOMELLA, L
    STERN, C
    MCALEER, C
    SEMINARS IN ONCOLOGY, 1995, 22 (05) : 41 - 45
  • [44] Vinorelbine-based chemotherapy in hormone-refractory prostate cancer
    Zampino, M. G.
    Verri, E.
    Locatelli, M.
    Curigliano, G.
    Ascione, G.
    Sbanotto, A.
    Rocca, A.
    Verweij, F.
    Matei, V.
    Scardino, E.
    Decobelli, O.
    Goldhirsch, A.
    Nole, F.
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2375 - 2380
  • [45] Etoposide and estramustine in previously treated hormone-refractory prostate cancer.
    Pavese, I.
    Di Palma, M.
    Mazzoli, M.
    Burattini, E.
    Satta, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
    Spitaleri, G.
    Matei, D. V.
    Curigliano, G.
    Detti, S.
    Verweij, F.
    Zambito, S.
    Scardino, E.
    Rocco, B.
    Nole, F.
    Ariu, L.
    De Pas, T.
    de Braud, F.
    De Cobelli, O.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 498 - 502
  • [47] Advantages of Second Line Estramustine for Overall Survival of Hormone-Refractory Prostate Cancer (HRPC) Patients
    Naiki, Taku
    Okamura, Takehiko
    Kawai, Noriyasu
    Sakagami, Hiroshi
    Yamada, Yasuyuki
    Fujita, Keiji
    Akita, Hidetoshi
    Hashimoto, Yoshihiro
    Tozawa, Keiichi
    Kohri, Kenjiro
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (01) : 71 - 74
  • [48] Docetaxel (D) plus estramustine monophosphate (EMP) in patients (pts) with hormone refractory prostate cancer (HRPC).
    Nelius, T
    Reiher, F
    Lindenmeir, T
    Burandt, J
    Rau, O
    Filleur, S
    Klatte, T
    Yap, R
    Allhoff, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 447S - 447S
  • [49] Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy
    Hirano, D
    Minei, S
    Kishimoto, Y
    Yamaguchi, K
    Hachiya, T
    Yoshida, T
    Yoshikawa, T
    Endoh, M
    Yamanaka, Y
    Yamamoto, T
    Satoh, Y
    Ishida, H
    Okada, K
    Takimoto, Y
    UROLOGIA INTERNATIONALIS, 2005, 75 (01) : 43 - 49
  • [50] Phase I/II study of taxane and estramustine with samarium in patients with hormone refractory prostate cancer.
    Arnsmeier, SL
    Spies, S
    Shervin, D
    Pins, M
    Bergan, RC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 439S - 439S
12345